Disclosures for "Evaluation of Dysphagia in Myositis and Muscular Dystrophy Using Real-time MRI and Quantitative Muscle Ultrasound"
-
Dr. Zeng has nothing to disclose.
-
Dr. Rietveld has nothing to disclose.
-
Dr. Al-Bourini has nothing to disclose.
-
Mrs. Kroon has nothing to disclose.
-
Prof. Olthoff has nothing to disclose.
-
Dr. Weidenmueller has nothing to disclose.
-
Dr. Carstens has nothing to disclose.
-
Mrs. Kommerell has nothing to disclose.
-
Dr. Schütz has nothing to disclose.
-
Dr. HORLINGS has nothing to disclose.
-
The institution of Dr. Kalf has received research support from Netherlands Organisation for Health Research and Development (ZonMw).
-
Bert de Swart has nothing to disclose.
-
The institution of Dr. van Engelen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum . The institution of Dr. van Engelen has received research support from Stichting Spieren voor Spieren. The institution of Dr. van Engelen has received research support from Prinses Beatrix Fonds. The institution of Dr. van Engelen has received research support from Dutch FSHD society. Dr. van Engelen has received intellectual property interests from a discovery or technology relating to health care.
-
Prof. Friede has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RECARDIO. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Daiichi Sankyo. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Prof. Friede has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BiosenseWebster. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Galapagos. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Enanta. Prof. Friede has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VICO Therapeutics. Prof. Friede has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Fresenius Kabi Deutschland GmbH.
-
Dr. Hofer has nothing to disclose.
-
Prof. Frahm has nothing to disclose.
-
The institution of Prof. Lotz has received research support from DFG. The institution of Prof. Lotz has received research support from BMBF.
-
Dr. Seif Amir Hosseini has nothing to disclose.
-
Dr. Schmidt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring and UCB. Dr. Schmidt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring and LFB. Dr. Schmidt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL Behring. Dr. Schmidt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Schmidt has received research support from Kezar, Novartis and AFM.
-
Dr. Saris has nothing to disclose.